Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: nuchemsciences.com
Number of Employees: 100
Year Founded: 2011
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
NuChem Sciences Inc. provides drug discovery and chemical development services in medicinal chemistry and the custom synthesis of small molecules and peptides. Its solutions include medicinal chemistry services, biochemistry support, and custom and contract synthesis; ADME/PK support, including drug distribution and stability (chemical and metabolic), drug-drug interaction, and toxicity studies; and in silico drug discovery using computational chemistry and molecular modeling, including virtual docking and ligand-based virtual screening. The company was serves biotechnology, pharmaceutical, academic research laboratories, and government institutions. NuChem Sciences Inc. was founded in 2011 and is based in Saint-Laurent, Canada. As of August 1, 2023, NuChem Sciences Inc. operates as a subsidiary of Sygnature Discovery Limited.


Financial Information (Currency: CAD, in mm)
Total Revenue
 38.6
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 100
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
LeBel, Marc 
President & Chairman of the Board
Montpetit, Patrick 
Chief Financial Officer
Guay, Daniel 
Chief Scientific Officer & Executive VP
Choquette, Lynda 
Director of Finance & Administration
Falardeau, Guy 
Head of Chemical Development

Key Board Members
Name
Title
LeBel, Marc 
President & Chairman of the Board


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
2350 rue Cohen Suite 201 | Saint-Laurent, QC | H4R 2N6 | Canada
Phone: 514-416-5659   Fax: 514-315-7539

Parent Company
Sygnature Discovery Limited

Prior Investors
Amorchem, AmorChem L.P.


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Inixium Inc.
Inixium Inc. provides services in recombinant protein production, biophysical characterization, protein crystallography, fragment screening and biologics, and biosimilars. The company was founded in 2014 and is based in Laval, Canada. As of October 31, 2022, Inixium Inc. operates as a subsidiary of NuChem Sciences Inc.

United States and Canada
Life Sciences Tools and Services
-
-
-
Omegachem Inc.
Omegachem Inc. engages in developing and producing organic compounds and reagents for pharmaceutical, biotechnological, and chemical industries in Canada and internationally. The company offers custom made intermediates, synthons and chirons, natural amino acid derivatives, functionalized heterocycles, building blocks, specialty reagents, fluorinated compounds, and chiral auxiliaries, as well as a range of fine chemicals. It also provides custom synthesis, contract research and development, sourcing, process optimization, and full time equivalent contract services. The company was founded in 1988 and is based in St-Romuald, Canada. As of August 10, 2021, Omegachem Inc. operates as a subsidiary of NuChem Sciences Inc.

United States and Canada
Life Sciences Tools and Services
14.00
-
-
Amplia PharmaTek Inc.
Amplia PharmaTek Inc. provides preclinical drug discovery and development services in biology. Its services include enzyme and cell-based assay development, compound screening, and in vivo pharmacology and pharmacokinetics studies. The company was founded in 2009 and is based in Montreal, Canada. As per the transaction announced on October 31, 2019, Amplia PharmaTek Inc. operates as a subsidiary of NuChem Therap

United States and Canada
Life Sciences Tools and Services
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-01-2023
Aug-01-2023
Merger/Acquisition
Target
NuChem Sciences Inc.
Sygnature Discovery Limited

-
Oct-31-2022
Oct-31-2022
Merger/Acquisition
Buyer
Inixium Inc.
NuChem Sciences Inc.

-
Aug-17-2021
Aug-10-2021
Merger/Acquisition
Buyer
Omegachem Inc.
NuChem Sciences Inc.

37.60
Oct-31-2019
-
Merger/Acquisition
Buyer
Amplia PharmaTek Inc.
NuChem Sciences Inc.

-
Feb-22-2019
Feb-22-2019
Merger/Acquisition
Target
NuChem Sciences Inc.

Amorchem Seller Funds:AmorChem L.P.
-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-01-2023
M&A Transaction Closings
Sygnature Discovery Limited acquired NuChem Sciences Inc.
Oct-31-2022
M&A Transaction Closings
NuChem Sciences Inc. acquired Inixium Inc.
Jun-20-2022
Business Expansions
NuChem Sciences Inaugurates its New State-of-the-Art Laboratories
Aug-17-2021
M&A Transaction Closings
NuChem Sciences Inc. acquired Omegachem Inc. for $37.6 million.
Oct-31-2019
M&A Transaction Announcements
NuChem Therapeutics Inc. acquired Amplia Pharmatek.

M&A Advisors
BCF LLP, Blake, Cassels & Graydon LLP, Fasken Campbell Godfrey, Fasken Martineau DuMoulin LLP


Advisors
M&A Advisors
BCF LLP, Blake, Cassels & Graydon LLP, Fasken Campbell Godfrey, Fasken Martineau DuMoulin LLP


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
LeBel, Marc 
President & Chairman of the Board
514-416-5659 (207)
514-315-7539
marc.lebel@nuchemrx.com
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
LeBel, Marc 
President & Chairman of the Board
514-416-5659 (207)
514-315-7539
marc.lebel@nuchemrx.com
Montpetit, Patrick 
Chief Financial Officer
514-416-5659
514-315-7539

Guay, Daniel 
Chief Scientific Officer & Executive VP
514-416-5659
514-315-7539
daniel.guay@nuchemrx.com
Choquette, Lynda 
Director of Finance & Administration
514-416-5659
514-315-7539
lynda.choquette@nuchemrx.com
Falardeau, Guy 
Head of Chemical Development
514-416-5659
514-315-7539

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
